Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23059276 | 0.81 | — | — | |
| SCHEMBL179564 | 0.81 | — | — | |
| SCHEMBL23059289 | 0.77 | PDE9A (0.37) | — | |
| SCHEMBL243654 | 0.73 | PI4KB (0.54) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL4572147 | 0.70 | ADORA2A (0.58) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL9884992 | 0.70 | ADORA2A (0.58) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL253874 | 0.70 | ADORA2A (0.58) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL30096023 | 0.69 | MTOR (0.41) | DHFRSLC2A1 | |
| SCHEMBL21459294 | 0.65 | CDK1 (0.44) | SLC2A1 | |
| SCHEMBL29399563 | 0.65 | CDK1 (0.44) | SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | ADORA2A 1787/4885ADORA2B 2523/4885ADORA1 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.